NCT03243331View on ClinicalTrials.gov

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 19, 2018

Primary Completion Date

May 27, 2020

Study Completion Date

May 27, 2020

Conditions
Triple Negative Breast CancerMetastatic Breast Cancer
Interventions
DRUG

Gedatolisib

Gedatolisb will be intravenously administered on Day 1, Day 8 and Day 15 of every 21 day cycle at a dose of 110 mg or 180mg depending on cohort assignment.

DRUG

PTK7-ADC

PTK7-ADC will be administered on Day 1 of every 21 day cycle at a dose of 1.4mg/kg or 2.8 mg/kg depending on cohort assignment.

Trial Locations (1)

46202

IU Simon Cancer Center, Indianapolis

All Listed Sponsors
lead

Kathy Miller

OTHER

NCT03243331 - An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer | Biotech Hunter | Biotech Hunter